Published ahead of print on January 24, 2003, doi:10.1164/rccm.200210-1157BC
Am. J. Respir. Crit. Care Med., Volume 167, Number 8, April 2003, 1139-1141
A more recent version of this article appeared on April 15, 2003
Submitted on October 12, 2002
Accepted on January 21, 2003
Sildenafil for long-term treatment of non-operable chronic thromboembolic pulmonary hypertension
Hossein A Ghofrani1, Ralph T Schermuly1, Frank Rose1, Ralph Wiedemann1, Markus G Kohstall1, Andre Kreckel1, Horst Olschewski1, Norbert Weissmann1, Beate Enke1, Stefanie Ghofrani1, Werner Seeger1, and Friedrich Grimminger1*
1 Internal Medicine, University Hospital, Justus-Liebig University Giessen, Giessen, Germany
* To whom correspondence should be addressed. E-mail: friedrich.grimminger{at}innere.med.uni-giessen.de.
Only a small percentage of patients with chronic thromboembolic pulmonary hypertension (CTEPH) are eligible for pulmonary thrombendarterectomy. We investigated the effects of oral sildenafil on hemodynamics and exercise capacity in 12 non-operable CTEPH patients. All patients were in disease progression despite sufficient long-term anticoagulation and best supportive care, and suffered from severe pulmonary hypertension (pulmonary vascular resistance index (PVRI) 1935+/-228 dyn*s*cm-5*m2, cardiac index (CI) 2.0 l*min-1*m-2, 6-min-walking distance 312+/-30 m). After approximately 6 months of sildenafil treatment, pulmonary hemodynamics and exercise capacity improved significantly (PVRI 1361+/-177 l*min-1*m2 (p=0.004), CI 2.4+/-0.2 l*min-1*m-2 (p=0.009), 6-minute-walking distance 366+/-28 m (p=0.02)). Therefore, oral sildenafil may offer a new option for medical treatment of this devastating disease.
Key words: Pulmonary hypertension, chronic thromboembolism, phosphodiesterase inhibitor, sildenafil
This article has been cited by other articles:

|
 |

|
 |
 
D. H. Freed, B. M. Thomson, S. S.L. Tsui, J. J. Dunning, K. K. Sheares, J. Pepke-Zaba, and D. P. Jenkins
Functional and haemodynamic outcome 1 year after pulmonary thromboendarterectomy.
Eur. J. Cardiothorac. Surg.,
September 1, 2008;
34(3):
525 - 530.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Hill, I. R. Preston, and K. E. Roberts
Inoperable Chronic Thromboembolic Pulmonary Hypertension: Treatable With Medical Therapy
Chest,
August 1, 2008;
134(2):
221 - 223.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Suntharalingam, C. M. Treacy, N. J. Doughty, K. Goldsmith, E. Soon, M. R. Toshner, K. K. Sheares, R. Hughes, N. W. Morrell, and J. Pepke-Zaba
Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chest,
August 1, 2008;
134(2):
229 - 236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
Eur. Respir. J.,
July 1, 2008;
32(1):
198 - 209.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Condliffe, D. G. Kiely, J. S. R. Gibbs, P. A. Corris, A. J. Peacock, D. P. Jenkins, D. Hodgkins, K. Goldsmith, R. J. Hughes, K. Sheares, et al.
Improved Outcomes in Medically and Surgically Treated Chronic Thromboembolic Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
May 15, 2008;
177(10):
1122 - 1127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Heart,
March 1, 2008;
94(Suppl_1):
i1 - i41.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Thorax,
March 1, 2008;
63(Suppl_2):
ii1 - ii41.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Reichenberger, R. Voswinckel, B. Enke, M. Rutsch, E. El Fechtali, T. Schmehl, H. Olschewski, R. Schermuly, N. Weissmann, H. A. Ghofrani, et al.
Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension
Eur. Respir. J.,
November 1, 2007;
30(5):
922 - 927.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Suntharalingam, R. D Machado, L. D Sharples, M. R Toshner, K. K Sheares, R. J Hughes, D. P Jenkins, R. C Trembath, N. W Morrell, and J. Pepke-Zaba
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension
Thorax,
July 1, 2007;
62(7):
617 - 622.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Takaoka, J. L. Faul, and R. Doyle
Current Therapies for Pulmonary Arterial Hypertension
Seminars in Cardiothoracic and Vascular Anesthesia,
June 1, 2007;
11(2):
137 - 148.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. Schermuly, S. S. Pullamsetti, G. Kwapiszewska, R. Dumitrascu, X. Tian, N. Weissmann, H. A. Ghofrani, C. Kaulen, T. Dunkern, C. Schudt, et al.
Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension: Target for Reverse-Remodeling Therapy
Circulation,
May 1, 2007;
115(17):
2331 - 2339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Fesler, A. Pagnamenta, B. Rondelet, F. Kerbaul, and R. Naeije
Effects of sildenafil on hypoxic pulmonary vascular function in dogs
J Appl Physiol,
October 1, 2006;
101(4):
1085 - 1090.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies
Cardiovasc Res,
October 1, 2006;
72(1):
30 - 40.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini
Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties.
Chest,
September 1, 2006;
130(3):
841 - 846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Galie and N. H. S. Kim
Pulmonary Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension
Proceedings of the ATS,
September 1, 2006;
3(7):
571 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bresser, J. Pepke-Zaba, X. Jais, M. Humbert, and M. M. Hoeper
Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm
Proceedings of the ATS,
September 1, 2006;
3(7):
594 - 600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Hughes, X. Jais, D. Bonderman, J. Suntharalingam, M. Humbert, I. Lang, G. Simonneau, and J. Pepke-Zaba
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Eur. Respir. J.,
July 1, 2006;
28(1):
138 - 143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Lang, M. Gomez-Sanchez, M. Kneussl, R. Naeije, P. Escribano, N. Skoro-Sajer, and J.-L. Vachiery
Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension
Chest,
June 1, 2006;
129(6):
1636 - 1643.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Hoeper, E. Mayer, G. Simonneau, and L. J. Rubin
Chronic Thromboembolic Pulmonary Hypertension
Circulation,
April 25, 2006;
113(16):
2011 - 2020.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Murata, K. Kinoshita, M. Hori, M. Kuwahara, H. Tsubone, H. Karaki, and H. Ozaki
Statin Protects Endothelial Nitric Oxide Synthase Activity in Hypoxia-Induced Pulmonary Hypertension
Arterioscler. Thromb. Vasc. Biol.,
November 1, 2005;
25(11):
2335 - 2342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Hoeper, T. Kramm, H. Wilkens, C. Schulze, H. J. Schafers, T. Welte, and E. Mayer
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chest,
October 1, 2005;
128(4):
2363 - 2367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Bonderman, R. Nowotny, N. Skoro-Sajer, J. Jakowitsch, C. Adlbrecht, W. Klepetko, and I. M. Lang
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chest,
October 1, 2005;
128(4):
2599 - 2603.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Rubin and D. B. Badesch
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
Ann Intern Med,
August 16, 2005;
143(4):
282 - 292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A A Aldashev, B K Kojonazarov, T A Amatov, T M Sooronbaev, M M Mirrakhimov, N W Morrell, J Wharton, and M R Wilkins
Phosphodiesterase type 5 and high altitude pulmonary hypertension
Thorax,
August 1, 2005;
60(8):
683 - 687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wharton, J. W. Strange, G. M. O. Moller, E. J. Growcott, X. Ren, A. P. Franklyn, S. C. Phillips, and M. R. Wilkins
Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells
Am. J. Respir. Crit. Care Med.,
July 1, 2005;
172(1):
105 - 113.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Dias-Junior, D. C. Souza-Costa, T. Zerbini, J. B. T. da Rocha, R. F. Gerlach, and J. E. Tanus-Santos
The Effect of Sildenafil on Pulmonary Embolism-Induced Oxidative Stress and Pulmonary Hypertension
Anesth. Analg.,
July 1, 2005;
101(1):
115 - 120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ng, S. J. Finney, R. Shulman, G. J. Bellingan, M. Singer, and P. A. Glynne
Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil?
Br. J. Anaesth.,
June 1, 2005;
94(6):
774 - 777.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. Richalet, P. Gratadour, P. Robach, I. Pham, M. Dechaux, A. Joncquiert-Latarjet, P. Mollard, J. Brugniaux, and J. Cornolo
Sildenafil Inhibits Altitude-induced Hypoxemia and Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
February 1, 2005;
171(3):
275 - 281.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J.,
December 2, 2004;
25(24):
2243 - 2278.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Rondelet, F. Kerbaul, R. Van Beneden, S. Motte, P. Fesler, I. Hubloue, M. Remmelink, S. Brimioulle, I. Salmon, J.-M. Ketelslegers, et al.
Signaling Molecules in Overcirculation-Induced Pulmonary Hypertension in Piglets: Effects of Sildenafil Therapy
Circulation,
October 12, 2004;
110(15):
2220 - 2225.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Raja and S. H. Nayak
Sildenafil: Emerging Cardiovascular Indications
Ann. Thorac. Surg.,
October 1, 2004;
78(4):
1496 - 1506.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Murata, M. Hori, K. Sakamoto, H. Karaki, and H. Ozaki
Dexamethasone Blocks Hypoxia-induced Endothelial Dysfunction in Organ-cultured Pulmonary Arteries
Am. J. Respir. Crit. Care Med.,
September 15, 2004;
170(6):
647 - 655.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, F. Reichenberger, M. G. Kohstall, E. H. Mrosek, T. Seeger, H. Olschewski, W. Seeger, and F. Grimminger
Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
Ann Intern Med,
August 3, 2004;
141(3):
169 - 177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Rubin and R. Naeije
Sildenafil for Enhanced Performance at High Altitude?
Ann Intern Med,
August 3, 2004;
141(3):
233 - 235.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-R. Chou, P.-H. Kuo, J.-C. Shih, and P.-C. Yang
A 31-Year-Old Pregnant Woman With Progressive Exertional Dyspnea and Differential Cyanosis
Chest,
August 1, 2004;
126(2):
638 - 641.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest,
July 1, 2004;
126(1_suppl):
35S - 62S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Doyle, D. McCrory, R. N. Channick, G. Simonneau, and J. Conte
Surgical Treatments/Interventions for Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest,
July 1, 2004;
126(1_suppl):
63S - 71S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, J. Pepke-Zaba, J. A. Barbera, R. Channick, A. M. Keogh, M. A. Gomez-Sanchez, M. Kneussl, and F. Grimminger
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12_Suppl_S):
68S - 72S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Bresser, P.F. Fedullo, W.R. Auger, R.N. Channick, I.M. Robbins, K.M. Kerr, S.W. Jamieson, and L.J. Rubin
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension
Eur. Respir. J.,
April 1, 2004;
23(4):
595 - 600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Tobin
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2003
Am. J. Respir. Crit. Care Med.,
January 15, 2004;
169(2):
301 - 313.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. H.S. Kim, P. Fesler, R. N. Channick, K. U. Knowlton, O. Ben-Yehuda, S. H. Lee, R. Naeije, and L. J. Rubin
Preoperative Partitioning of Pulmonary Vascular Resistance Correlates With Early Outcome After Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension
Circulation,
January 6, 2004;
109(1):
18 - 22.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 American Thoracic Society
|
|
|